J Kellogg Parsons1,2,3, John P Pierce4, James Mohler5, Electra Paskett6, Sin-Ho Jung7, Michael J Morris8, Eric Small9, Olwen Hahn10, Peter Humphrey11, John Taylor12, James Marshall12. 1. Division of Urologic Oncology, UC San Diego Moores Comprehensive Cancer Center, La Jolla, CA, USA. 2. Department of Urology, UC San Diego Health System, La Jolla, CA, USA. 3. VA San Diego Healthcare System, La Jolla, CA, USA. 4. Department of Family Medicine and Public Health and Moores Cancer Center, University of California, San Diego, La Jolla, CA, USA. 5. Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA. 6. Department of Medicine, College of Medicine, Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA. 7. Alliance Statistics and Data Center, Duke University, Durham, NC, USA. 8. Memorial Sloan Kettering Cancer Center, New York, NY, USA. 9. UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. 10. Alliance Central Protocol Operations, University of Chicago, Chicago, IL, USA. 11. Department of Pathology, Yale University Medical School, New Haven, CT, USA. 12. Department of Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY, USA.
Abstract
OBJECTIVE: To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. METHODS: The Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]) is a phase III clinical trial testing the efficacy of a high-vegetable diet to prevent progression in patients with prostate cancer on active surveillance (AS). Participants were randomized to a validated diet counselling intervention or to a control condition. Chi-squared and Kruskal-Wallis analyses were used to assess between-group differences at baseline. RESULTS:Between 2011 and 2015, 478 (103%) of a targeted 464 patients were randomized at 91 study sites. At baseline, the mean (sd) age was 64 (6) years and mean (sd) PSA concentration was 4.9 (2.1) ng/mL. Fifty-six (12%) participants were African-American, 17 (4%) were Hispanic/Latino, and 16 (3%) were Asian-American. There were no significant between-group differences for age (P = 0.98), race/ethnicity (P = 0.52), geographic region (P = 0.60), time since prostate cancer diagnosis (P = 0.85), PSA concentration (P = 0.96), clinical stage (T1c or T2a; P = 0.27), or Gleason sum (Gleason 6 or 3+4 = 7; P = 0.76). In a pre-planned analysis, the baseline prostate biopsy samples of the first 50 participants underwent central pathology review to confirm eligibility, with an expectation that <10% would become ineligible. One of 50 participants (2%) became ineligible. CONCLUSION: The MEAL study shows the feasibility of implementing national, multi-institutional phase III clinical trials of diet for prostate cancer and of testing interventions to prevent disease progression in AS.
RCT Entities:
OBJECTIVE: To assess the feasibility of performing national, randomized trials of dietary interventions for localized prostate cancer. METHODS: The Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]) is a phase III clinical trial testing the efficacy of a high-vegetable diet to prevent progression in patients with prostate cancer on active surveillance (AS). Participants were randomized to a validated diet counselling intervention or to a control condition. Chi-squared and Kruskal-Wallis analyses were used to assess between-group differences at baseline. RESULTS: Between 2011 and 2015, 478 (103%) of a targeted 464 patients were randomized at 91 study sites. At baseline, the mean (sd) age was 64 (6) years and mean (sd) PSA concentration was 4.9 (2.1) ng/mL. Fifty-six (12%) participants were African-American, 17 (4%) were Hispanic/Latino, and 16 (3%) were Asian-American. There were no significant between-group differences for age (P = 0.98), race/ethnicity (P = 0.52), geographic region (P = 0.60), time since prostate cancer diagnosis (P = 0.85), PSA concentration (P = 0.96), clinical stage (T1c or T2a; P = 0.27), or Gleason sum (Gleason 6 or 3+4 = 7; P = 0.76). In a pre-planned analysis, the baseline prostate biopsy samples of the first 50 participants underwent central pathology review to confirm eligibility, with an expectation that <10% would become ineligible. One of 50 participants (2%) became ineligible. CONCLUSION: The MEAL study shows the feasibility of implementing national, multi-institutional phase III clinical trials of diet for prostate cancer and of testing interventions to prevent disease progression in AS.
Authors: Neil E Fleshner; M Scott Lucia; Blair Egerdie; Lorne Aaron; Gregg Eure; Indrani Nandy; Libby Black; Roger S Rittmaster Journal: Lancet Date: 2012-01-24 Impact factor: 79.321
Authors: Dean Ornish; Jue Lin; June M Chan; Elissa Epel; Colleen Kemp; Gerdi Weidner; Ruth Marlin; Steven J Frenda; Mark Jesus M Magbanua; Jennifer Daubenmier; Ivette Estay; Nancy K Hills; Nita Chainani-Wu; Peter R Carroll; Elizabeth H Blackburn Journal: Lancet Oncol Date: 2013-09-17 Impact factor: 41.316
Authors: Dean Ornish; Gerdi Weidner; William R Fair; Ruth Marlin; Elaine B Pettengill; Caren J Raisin; Stacey Dunn-Emke; Lila Crutchfield; F Nicholas Jacobs; R James Barnard; William J Aronson; Patricia McCormac; Damien J McKnight; Jordan D Fein; Ann M Dnistrian; Jeanmaire Weinstein; Tung H Ngo; Nancy R Mendell; Peter R Carroll Journal: J Urol Date: 2005-09 Impact factor: 7.450
Authors: Debasish Sundi; Farzana A Faisal; Bruce J Trock; Patricia K Landis; Zhaoyong Feng; Ashley E Ross; H Ballentine Carter; Edward M Schaeffer Journal: Urology Date: 2014-10-14 Impact factor: 2.649
Authors: Jeffrey J Tosoian; Bruce J Trock; Patricia Landis; Zhaoyong Feng; Jonathan I Epstein; Alan W Partin; Patrick C Walsh; H Ballentine Carter Journal: J Clin Oncol Date: 2011-04-04 Impact factor: 44.544
Authors: Ke Zu; Lorelei Mucci; Bernard A Rosner; Steven K Clinton; Massimo Loda; Meir J Stampfer; Edward Giovannucci Journal: J Natl Cancer Inst Date: 2014-01-24 Impact factor: 13.506
Authors: J Kellogg Parsons; Vicky A Newman; James L Mohler; John P Pierce; Shirley Flatt; James Marshall Journal: BJU Int Date: 2008-01-24 Impact factor: 5.588
Authors: Jeannette M Schenk; Marian L Neuhouser; Sarah J Beatty; Matthew VanDoren; Daniel W Lin; Michael Porter; John L Gore; Roman Gulati; Stephen R Plymate; Jonathan L Wright Journal: Contemp Clin Trials Date: 2019-04-16 Impact factor: 2.226
Authors: Michael A Liss; Osamah Al-Bayati; Jonathan Gelfond; Martin Goros; Sarah Ullevig; John DiGiovanni; Jill Hamilton-Reeves; Denise O'Keefe; Dean Bacich; Brandi Weaver; Robin Leach; Ian M Thompson Journal: Prostate Cancer Prostatic Dis Date: 2018-11-01 Impact factor: 5.554
Authors: Justin R Gregg; Jiali Zheng; David S Lopez; Chad Reichard; Gladys Browman; Brian Chapin; Jeri Kim; John Davis; Carrie R Daniel Journal: Br J Cancer Date: 2019-01-25 Impact factor: 7.640
Authors: Melissa García-Caballero; José Antonio Torres-Vargas; Ana Dácil Marrero; Beatriz Martínez-Poveda; Miguel Ángel Medina; Ana R Quesada Journal: Pharmaceutics Date: 2022-01-21 Impact factor: 6.321